Latin America and the Caribbean vs Mongolia: Proportion of the target population who received a 3rd dose of
Latin America and the Caribbean
76.0%
in 2024
Mongolia
96.0%
in 2024
Latin America and the Caribbean rank
17th
Mongolia rank
16th
Proportion of the target population who received a 3rd dose of over time
- Latin America and the Caribbean
- Mongolia
How they compare
Mongolia currently reports 96.0% against 76.0% in Latin America and the Caribbean, a difference of 20.0%.
That makes Mongolia's figure about 1.3 times Latin America and the Caribbean's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Latin America and the Caribbean ahead.
Latin America and the Caribbean ranks 17th and Mongolia ranks 16th of 37 groups.
Across the 2 decades both report, Latin America and the Caribbean averaged higher in 1 and Mongolia in 1.
Head to head by decade
| Decade | Latin America and the Caribbean | Mongolia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 77.7% | 29.3% | 48.3% | Latin America and the Caribbean |
| 2020s | 73.4% | 94.6% | 21.2% | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received a 3rd dose of, Latin America and the Caribbean or Mongolia?
- Mongolia, at 96.0% against 76.0% in Latin America and the Caribbean as of 2024.
- What is the difference in proportion of the target population who received a 3rd dose of between Latin America and the Caribbean and Mongolia?
- 20.0%, with Mongolia ahead.
- How many years of comparable data are there for Latin America and the Caribbean and Mongolia?
- 8 years are reported by both, from 2017 to 2024.
- How do Latin America and the Caribbean and Mongolia rank globally for proportion of the target population who received a 3rd dose of?
- Latin America and the Caribbean ranks 17th and Mongolia ranks 16th of 37 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.